Alcohol, genetics and risk of breast cancer in the Prostate, Lung, Colorectal and Ovarian (PLCO) Cancer Screening Trial

被引:0
|
作者
Catherine A. McCarty
Douglas J. Reding
John Commins
Craig Williams
Meredith Yeager
James K. Burmester
Catherine Schairer
Regina G. Ziegler
机构
[1] Essentia Institute of Rural Health,
[2] Marshfield Clinic Research Foundation,undefined
[3] Information Management Services,undefined
[4] Inc.,undefined
[5] National Cancer Institute,undefined
来源
关键词
Breast cancer; Alcohol; Metabolizing enzyme; Genetics; Risk factors;
D O I
暂无
中图分类号
学科分类号
摘要
We tested the hypothesis that genes involved in the alcohol oxidation pathway modify the association between alcohol intake and breast cancer. Subjects were women aged 55–74 at baseline from the screening arm of the Prostate, Lung, Colorectal, and Ovarian (PLCO) Cancer Screening Trial. Incident breast cancers were identified through annual health surveys. Controls were frequency matched to cases by age and year of entry into the trial. A self-administered food frequency questionnaire queried frequency and usual serving size of beer, wine or wine coolers, and liquor. Three SNPs in genes in the alcohol metabolism pathway were genotyped: alcohol dehydrogenase 2, alcohol dehydrogenase 3, and CYP2E1. The study included 1,041 incident breast cancer cases and 1,070 controls. In comparison to non-drinkers, the intake of any alcohol significantly increased the risk of breast cancer, and this risk increased with each category of daily alcohol intake (OR 2.01, 95% CI 1.14, 3.53) for women who drank three or more standard drinks per day. Stratification by genotype revealed significant gene/environment interactions. For the ADH1B gene, there were statistically significant associations between all levels of alcohol intake and risk of breast cancer (all OR > 1.34 and all lower CI > 1.01), while for women with the GA or AA genotype, there were no significant associations between alcohol intake and risk of breast cancer. Alcohol intake, genes involved in alcohol metabolism and their interaction increase the risk of breast cancer in post-menopausal women. This information could be useful for primary care providers to personalize information about breast cancer risk reduction.
引用
收藏
页码:785 / 792
页数:7
相关论文
共 50 条
  • [31] Quality control of cancer screening examination procedures in the Prostate, Lung, Colorectal and Ovarian (PLCO) Cancer Screening Trial
    Weissfeld, JL
    Fagerstrom, RM
    O'Brien, B
    [J]. CONTROLLED CLINICAL TRIALS, 2000, 21 (06): : 390S - 399S
  • [32] PROSTATE CANCER DETECTION WITH DIGITAL RECTAL EXAM IN THE PROSTATE LUNG COLORECTAL AND OVARIAN (PLCO) CANCER SCREENING TRIAL
    Halpern, Joshua
    Shoag, Jonathan
    Mittel, Sameer
    Lipsitz, Stuart
    Ballman, Karla
    Hu, Jim
    [J]. JOURNAL OF UROLOGY, 2016, 195 (04): : E548 - E549
  • [33] Ovarian cancer screening in the Prostate, Lung, Colorectal and Ovarian (PLCO) cancer screening trial: Findings from the initial screen of a randomized trial
    Buys, SS
    Partridge, E
    Greene, MH
    Prorok, PC
    Reding, D
    Riley, TL
    Hartge, P
    Fagerstrom, RM
    Chia, D
    Izmirlian, G
    Fouad, M
    Ragard, LR
    Johnson, CC
    Gohagan, JK
    [J]. AMERICAN JOURNAL OF OBSTETRICS AND GYNECOLOGY, 2005, 193 (05) : 1630 - 1639
  • [34] Prediagnostic White Blood Cell DNA Methylation and Risk of Breast Cancer in the Prostate Lung, Colorectal, and Ovarian Cancer Screening Trial (PLCO) Cohort
    Sturgeon, Susan R.
    Sela, David A.
    Browne, Eva P.
    Einson, Jonah
    Rani, Asha
    Halabi, Mohamed
    Kania, Thomas
    Keezer, Andrew
    Balasubramanian, Raji
    Ziegler, Regina G.
    Schairer, Catherine
    Kelsey, Karl T.
    Arcaro, Kathleen F.
    [J]. CANCER EPIDEMIOLOGY BIOMARKERS & PREVENTION, 2021, 30 (08) : 1575 - 1581
  • [35] Folate intake, alcohol use, and postmenopausal breast cancer risk in the Prostate, Lung, Colorectal, and Ovarian Cancer Screening Trial
    Stolzenberg-Solomon, RZ
    Chang, SC
    Leitzmann, MF
    Johnson, KA
    Johnson, C
    Buys, SS
    Hoover, RN
    Ziegler, RG
    [J]. AMERICAN JOURNAL OF CLINICAL NUTRITION, 2006, 83 (04): : 895 - 904
  • [36] DNA repair polymorphisms and risk of colorectal adenoma in the Prostate, Lung, Colorectal, and Ovarian (PLCO) Cancer Screening Trial.
    Huang, WY
    Kang, D
    Weissfeld, JL
    Bresalier, RS
    Hayes, RB
    [J]. AMERICAN JOURNAL OF EPIDEMIOLOGY, 2002, 155 (11) : s4 - s4
  • [37] Body mass index (BMI), change in BMI, and postmenopausal breast cancer risk in the Prostate, Lung, Colorectal, and Ovarian Cancer Screening Trial (PLCO)
    Sue, Laura Y.
    Genkinger, Jeanine M.
    Schairer, Catherine
    Ziegler, Regina G.
    [J]. CANCER RESEARCH, 2010, 70
  • [38] Prostate cancer screening in the prostate, lung, colorectal and Ovarian (PLCO) Cancer Screening Trial: Findings from the initial screening round of a randomized trial
    Andriole, GL
    Levin, DL
    Crawford, ED
    Gelmann, ER
    Pinsky, PF
    Chia, D
    Kramer, BS
    Reding, D
    Church, TR
    Grubb, RL
    Izmirlian, G
    Ragard, LR
    Clapp, JD
    Prorok, PC
    Gohagan, JK
    [J]. JNCI-JOURNAL OF THE NATIONAL CANCER INSTITUTE, 2005, 97 (06) : 433 - 438
  • [39] Prediagnostic Serum Levels of Fatty Acid Metabolites and Risk of Ovarian Cancer in the Prostate, Lung, Colorectal, and Ovarian (PLCO) Cancer Screening Trial
    Hada, Manila
    Edin, Matthew L.
    Hartge, Patricia
    Lih, Fred B.
    Wentzensen, Nicolas
    Zeldin, Darryl C.
    Trabert, Britton
    [J]. CANCER EPIDEMIOLOGY BIOMARKERS & PREVENTION, 2019, 28 (01) : 189 - 197
  • [40] Serum vitamin D and risk of prostate cancer among black men in the Prostate, Lung, Colorectal, and Ovarian (PLCO) Cancer Screening Trial
    Layne, Tracy M.
    Weinstein, Stephanie
    Ma, Xiaomei
    Graubard, Barry I.
    Mayne, Susan T.
    Albanes, Demetrius
    [J]. CANCER EPIDEMIOLOGY BIOMARKERS & PREVENTION, 2016, 25 (03)